메뉴 건너뛰기




Volumn 16, Issue 12, 2007, Pages 1967-1975

The role of azacitidine in the treatment of myelodysplastic syndromes

Author keywords

Azacitidine; Methylation; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; CYCLOSPORIN A; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; STEROID; THYMOCYTE ANTIBODY; ANTINEOPLASTIC ANTIMETABOLITE;

EID: 39549103104     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.12.1967     Document Type: Article
Times cited : (18)

References (33)
  • 1
    • 40949127088 scopus 로고    scopus 로고
    • Myelodysplastic syndromes: Biology and treatment
    • 4th Edition. Hoffman R Ed, Elsevier, Churchill Livingston Publishers, Philadelphia
    • DE ANGELO D, STONE R: Myelodysplastic syndromes: biology and treatment. In: Hoffman: Hematology: Basic Principles and Practice, 4th Edition. Hoffman R (Ed.), Elsevier, Churchill Livingston Publishers, Philadelphia (2005):67.
    • (2005) Hoffman: Hematology: Basic Principles and Practice , pp. 67
    • DE ANGELO, D.1    STONE, R.2
  • 2
    • 0017162163 scopus 로고
    • Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative groups
    • BENNETT JM, CATOVSKY D, DANIEL MT et al.: Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative groups. Br. J. Haematol. (1976) 33:451-458.
    • (1976) Br. J. Haematol , vol.33 , pp. 451-458
    • BENNETT, J.M.1    CATOVSKY, D.2    DANIEL, M.T.3
  • 3
    • 0036786901 scopus 로고    scopus 로고
    • The World Health Organization (WHO) classification of the myeloid neoplasms
    • VARDIMAN JW, HARRIS NL, BRUNNING RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 100:2292-2302.
    • (2002) Blood , vol.100 , pp. 2292-2302
    • VARDIMAN, J.W.1    HARRIS, N.L.2    BRUNNING, R.D.3
  • 4
    • 0030897009 scopus 로고    scopus 로고
    • International scoring system for evaluating prognosis in myelodysplastic syndromes
    • GREENBERG P, COX C, LEBEAU MM et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 89:2079-2088.
    • (1997) Blood , vol.89 , pp. 2079-2088
    • GREENBERG, P.1    COX, C.2    LEBEAU, M.M.3
  • 5
    • 33947265592 scopus 로고    scopus 로고
    • Recent advances in myelodysplastic syndromes
    • SHADDUCK R, LATSKO J, ROSSETTI J et al.: Recent advances in myelodysplastic syndromes. Exp. Haematol. (2007) 35:137-143.
    • (2007) Exp. Haematol , vol.35 , pp. 137-143
    • SHADDUCK, R.1    LATSKO, J.2    ROSSETTI, J.3
  • 6
    • 0001583359 scopus 로고
    • The activity of a new antimetabolite, 5-azacytidine, against lymphoid leukaemia in AK mice
    • SORM F, VESELY J: The activity of a new antimetabolite, 5-azacytidine, against lymphoid leukaemia in AK mice. Neoplasma (1964) 11:123.
    • (1964) Neoplasma , vol.11 , pp. 123
    • SORM, F.1    VESELY, J.2
  • 7
    • 0142216208 scopus 로고    scopus 로고
    • Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
    • LEONE G, VOSO M, TEOFILI L et al.: Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin. Immunol. (2003) 109:89-102.
    • (2003) Clin. Immunol , vol.109 , pp. 89-102
    • LEONE, G.1    VOSO, M.2    TEOFILI, L.3
  • 8
    • 0030612423 scopus 로고    scopus 로고
    • INK4B gene in myelodysplastic syndromes
    • INK4B gene in myelodysplastic syndromes. Blood (1997) 90:1403-1409.
    • (1997) Blood , vol.90 , pp. 1403-1409
    • UCHIDA, T.1    KINOSHITA, T.2    NAGAI, H.3
  • 10
    • 0033988813 scopus 로고    scopus 로고
    • DNA methyltransferase DNMT1 associates with histone deacetylase activity
    • FUKS F, BURGERS WA, BREHM A et al.: DNA methyltransferase DNMT1 associates with histone deacetylase activity. Nat. Genet. (2000) 24:88-91.
    • (2000) Nat. Genet , vol.24 , pp. 88-91
    • FUKS, F.1    BURGERS, W.A.2    BREHM, A.3
  • 11
    • 24344435916 scopus 로고    scopus 로고
    • ASIF M, SIDDIQUI A, J SCOTT L: Azacitidine in myelodysplastic syndromes. Drugs (2005) 65:1781-1789.
    • ASIF M, SIDDIQUI A, J SCOTT L: Azacitidine in myelodysplastic syndromes. Drugs (2005) 65:1781-1789.
  • 12
    • 0029013514 scopus 로고
    • Induction of apoptosis by 5-azacitidine: Drug concentration-dependent differences in cell cycle specificity
    • MURAKAMI T, LI X, GONG J et al.: Induction of apoptosis by 5-azacitidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res. (1995) 55:3093-3098.
    • (1995) Cancer Res , vol.55 , pp. 3093-3098
    • MURAKAMI, T.1    LI, X.2    GONG, J.3
  • 13
    • 0043023499 scopus 로고    scopus 로고
    • Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin M, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia
    • LOPEZ-KARPOVITCH X, BARRALES-BENITEZ O, FLORES M et al.: Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin M, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia. Cytokine (2002) 20:154-162.
    • (2002) Cytokine , vol.20 , pp. 154-162
    • LOPEZ-KARPOVITCH, X.1    BARRALES-BENITEZ, O.2    FLORES, M.3
  • 14
    • 17644404081 scopus 로고    scopus 로고
    • Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes
    • MARCUCCI G, SILVERMAN L, ELLER M et al.: Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J. Clin. Pharmacol. (2005) 45:597-602.
    • (2005) J. Clin. Pharmacol , vol.45 , pp. 597-602
    • MARCUCCI, G.1    SILVERMAN, L.2    ELLER, M.3
  • 15
    • 40949101902 scopus 로고    scopus 로고
    • An oral dosage formulation of azacitidine: A pilot pharmacokinetic study
    • WARD MR, STOLTZ ML, ETTER JB et al.: An oral dosage formulation of azacitidine: a pilot pharmacokinetic study. ASCO Annual Meeting Proceedings (2007) 25:7084.
    • (2007) ASCO Annual Meeting Proceedings , vol.25 , pp. 7084
    • WARD, M.R.1    STOLTZ, M.L.2    ETTER, J.B.3
  • 16
    • 0027154222 scopus 로고
    • Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
    • SILVERMAN LR, HOLLAND JF, WEINBERG RS: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia (1993) 7(Suppl. 1):21-29.
    • (1993) Leukemia , vol.7 , Issue.SUPPL. 1 , pp. 21-29
    • SILVERMAN, L.R.1    HOLLAND, J.F.2    WEINBERG, R.S.3
  • 17
    • 0002858015 scopus 로고
    • Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921
    • SILVERMAN LR, HOLLAND JF, DEMAKOS EP et al.: Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann. Hematol. (1994) 68(Suppl. 1):A12.
    • (1994) Ann. Hematol , vol.68 , Issue.SUPPL. 1
    • SILVERMAN, L.R.1    HOLLAND, J.F.2    DEMAKOS, E.P.3
  • 18
    • 0025831445 scopus 로고
    • Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes
    • CHITAMBAR CR, LIBNOCH JA, MATTHAEUS WG et al.: Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am. J. Hematol. (1991) 37:100-104.
    • (1991) Am. J. Hematol , vol.37 , pp. 100-104
    • CHITAMBAR, C.R.1    LIBNOCH, J.A.2    MATTHAEUS, W.G.3
  • 19
    • 0037093195 scopus 로고    scopus 로고
    • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
    • SILVERMAN LR, DEMAKOS EP, PETERSON BL et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. (2002) 20:2429-2440.
    • (2002) J. Clin. Oncol , vol.20 , pp. 2429-2440
    • SILVERMAN, L.R.1    DEMAKOS, E.P.2    PETERSON, B.L.3
  • 20
    • 0037092962 scopus 로고    scopus 로고
    • Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: A cancer and leukemia group B study
    • KORNBLITH AB, HERNDON JE, SILVERMAN LR et al.: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: a cancer and leukemia group B study. J. Clin. Oncol. (2002) 20:2441-2452.
    • (2002) J. Clin. Oncol , vol.20 , pp. 2441-2452
    • KORNBLITH, A.B.1    HERNDON, J.E.2    SILVERMAN, L.R.3
  • 21
    • 33748474416 scopus 로고    scopus 로고
    • Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the cancer and leukemia group B
    • SILVERMAN LR, MCKENZIE DR, PETERSON BL et al.: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J. Clin. Oncol. (2006) 24:3895-3903.
    • (2006) J. Clin. Oncol , vol.24 , pp. 3895-3903
    • SILVERMAN, L.R.1    MCKENZIE, D.R.2    PETERSON, B.L.3
  • 22
    • 0036342388 scopus 로고    scopus 로고
    • Treatment of myelodysplastic syndromes with 5-azacytidine
    • GRYN J, ZIEGLER Z, SHADDUCK R et al.: Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk. Res. (2002) 26:893-897.
    • (2002) Leuk. Res , vol.26 , pp. 893-897
    • GRYN, J.1    ZIEGLER, Z.2    SHADDUCK, R.3
  • 24
    • 33750078985 scopus 로고    scopus 로고
    • Treatment of acute myelogenous leukemia with outpatient azacitidine
    • SUDAN N, ROSSETTI JM, SHADDUCK R et al.: Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer (2006) 107:1839-1843.
    • (2006) Cancer , vol.107 , pp. 1839-1843
    • SUDAN, N.1    ROSSETTI, J.M.2    SHADDUCK, R.3
  • 25
    • 79960971189 scopus 로고    scopus 로고
    • Transcription modulation; a pilot study of sodium phenylbutyrate plus 5-azacytidine
    • CAMACHO L, RYAN HJ, CHANEL S et al.: Transcription modulation; a pilot study of sodium phenylbutyrate plus 5-azacytidine. Blood (2001) 98(Suppl. 1):A460.
    • (2001) Blood , vol.98 , Issue.SUPPL. 1
    • CAMACHO, L.1    RYAN, H.J.2    CHANEL, S.3
  • 26
    • 79960971544 scopus 로고    scopus 로고
    • A Phase I dose-descalation trial of combined DNA methyltransferase (MeT)/histone deacetylase (HDAC) inhibition in myeloid malignancies
    • MILLER CB, HERMAN JG, BAYLIN SB et al.: A Phase I dose-descalation trial of combined DNA methyltransferase (MeT)/histone deacetylase (HDAC) inhibition in myeloid malignancies. Blood (2001) 98(Suppl. 1):A622.
    • (2001) Blood , vol.98 , Issue.SUPPL. 1
    • MILLER, C.B.1    HERMAN, J.G.2    BAYLIN, S.B.3
  • 27
    • 34848865289 scopus 로고
    • Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
    • Abstract
    • GARCIA-MANERO G, YANG AS, GILES F et al.: Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Blood (2006) 108:(Abstract 1954).
    • (1954) Blood , vol.108
    • GARCIA-MANERO, G.1    YANG, A.S.2    GILES, F.3
  • 28
    • 40949157668 scopus 로고    scopus 로고
    • Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes
    • Abstract 7083
    • LYONS RM, COSGRIFF T, MODI S et al.: Tolerability and hematologic improvement assessed using three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. ASCO Annual Meeting Proceedings (2007) 25:(Abstract 7083).
    • (2007) ASCO Annual Meeting Proceedings , vol.25
    • LYONS, R.M.1    COSGRIFF, T.2    MODI, S.3
  • 29
    • 34848928673 scopus 로고    scopus 로고
    • G-CSF increases hematological response among patients with myelodysplasia treated with azacitidine
    • Abstract 4868
    • ROSSETTI JM, FALKE E, SHADDUCK RK et al.: G-CSF increases hematological response among patients with myelodysplasia treated with azacitidine. Blood (2006) 108:(Abstract 4868).
    • (2006) Blood , vol.108
    • ROSSETTI, J.M.1    FALKE, E.2    SHADDUCK, R.K.3
  • 30
    • 40949083161 scopus 로고    scopus 로고
    • G-CSF increases hematological response and survival among patients with myelodysplasia treated with azacitidine, Florence, Italy 2007, Poster presentation
    • FALKE E, ROSSETTI JM, SAHDDUCK RK et al.: G-CSF increases hematological response and survival among patients with myelodysplasia treated with azacitidine. The 9th International Symposium on Myelodysplastic Syndromes, Florence, Italy (2007) (Poster presentation).
    • The 9th International Symposium on Myelodysplastic Syndromes
    • FALKE, E.1    ROSSETTI, J.M.2    SAHDDUCK, R.K.3
  • 31
    • 3142580475 scopus 로고    scopus 로고
    • A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome
    • CUTLER CS, LEE SJ, GREENBERG P et al.: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood (2004) 104:579-585.
    • (2004) Blood , vol.104 , pp. 579-585
    • CUTLER, C.S.1    LEE, S.J.2    GREENBERG, P.3
  • 32
    • 40949136638 scopus 로고    scopus 로고
    • Pre-transplant 5-azacitidine (Vidaza) may improve outcome of allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS)
    • Abstract 3664
    • FIELD T, PERKINS J, ALSINA M et al.: Pre-transplant 5-azacitidine (Vidaza) may improve outcome of allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS). Blood (2006) 108:(Abstract 3664).
    • (2006) Blood , vol.108
    • FIELD, T.1    PERKINS, J.2    ALSINA, M.3
  • 33
    • 72249095950 scopus 로고    scopus 로고
    • Maintenance therapy with 5-azacitidine after allogeneic stem cell transplantation for acute myelogenous leukemia and high-risk myelodysplastic syndrome (MDS): A dose and schedule finding study
    • Abstract 3668
    • SORIANO A, CHAMPLIN R, MCCORMICK G et al.: Maintenance therapy with 5-azacitidine after allogeneic stem cell transplantation for acute myelogenous leukemia and high-risk myelodysplastic syndrome (MDS): a dose and schedule finding study. Blood (2006) 108:(Abstract 3668).
    • (2006) Blood , vol.108
    • SORIANO, A.1    CHAMPLIN, R.2    MCCORMICK, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.